Skip to main content

ICH E1 The extent of population exposure to assess clinical safety (CPMP/ICH/375/95)

 The ICH E1 guideline, titled "The Extent of Population Exposure to Assess Clinical Safety," is an important document developed by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). This guideline, with the reference number CPMP/ICH/375/95, provides recommendations and principles for assessing the safety of new drugs during clinical development by considering the extent of population exposure. Here's an elaboration of ICH E1:


1. Purpose:

The primary purpose of ICH E1 is to guide the pharmaceutical industry and regulatory authorities in assessing the safety of new drugs through the evaluation of the extent to which the drug is exposed to human populations during clinical development.

2. Population Exposure:

The guideline emphasizes the importance of evaluating the extent of exposure of the drug to different populations, including the target patient population, special populations (e.g., pediatrics, elderly), and populations likely to be exposed after marketing (e.g., healthcare providers, caregivers).

3. Risk Assessment:

ICH E1 underscores the significance of conducting a comprehensive safety risk assessment by considering the number of exposed patients, the duration of exposure, the dose, and the route of administration. This assessment helps identify and characterize potential safety concerns.

4. Special Populations:

Special populations, such as pediatric and elderly patients, pregnant or breastfeeding women, and patients with specific medical conditions, may require additional consideration in terms of safety assessment and exposure.

5. Risk-Benefit Evaluation:

The guideline encourages a thorough evaluation of the benefit-risk profile of the drug. This includes assessing the potential benefits of the drug against identified safety concerns based on exposure data.

6. Pharmacovigilance Planning:

ICH E1 discusses the importance of planning for post-marketing pharmacovigilance, considering the extent of population exposure during clinical trials. Timely and accurate reporting of adverse events is crucial for ongoing safety assessment.

7. Regulatory Submissions:

The guideline provides guidance on the inclusion of exposure data and safety assessments in regulatory submissions, including new drug applications. It emphasizes that these data are essential for regulatory decision-making.

8. Global Harmonization:

ICH E1 aims to harmonize safety assessment practices across different regions and countries, promoting consistency in evaluating the extent of population exposure and its implications for safety.

9. Risk Communication:

Effective communication of safety information to healthcare professionals, patients, and the public is highlighted. Transparent and accurate information helps ensure that the benefits and risks of the drug are understood.

10. Update and Adaptation:

- The guideline acknowledges the evolving nature of drug development and safety assessment. It encourages the continuous updating and adaptation of safety assessments as new exposure data become available.


In summary, ICH E1 provides a framework for assessing the safety of new drugs by considering the extent of population exposure during clinical development. It promotes a comprehensive evaluation of exposure data, risk assessment, and benefit-risk analysis to support informed regulatory decisions and safe use of medicines. Compliance with this guideline is crucial for pharmaceutical companies and regulatory authorities to ensure that the safety of new drugs is adequately assessed and communicated to healthcare professionals and patients

Labels:

Popular posts from this blog

Ago2 Immunoprecipitation for RISC-siRNA Quantitation

 Ago2 (Argonaute 2) immunoprecipitation (IP) is a technique used to isolate RNA-induced silencing complexes (RISC) from cell lysates. This method allows for the specific enrichment of active RISC complexes bound to small interfering RNA (siRNA) or microRNA (miRNA) within cells. By isolating these complexes, researchers can then quantify the siRNA associated with Ago2, which is an essential step in determining the efficacy of RISC loading and siRNA activity. Here’s a detailed overview of how Ago2 immunoprecipitation is performed for RISC-siRNA quantitation: Steps in Ago2 Immunoprecipitation for RISC-siRNA Quantitation Cell Lysis and Preparation of Lysate : Sample Preparation : Collect cells that have been treated with siRNA, then wash them with cold phosphate-buffered saline (PBS) to remove extracellular contaminants. Lysis : Lyse the cells in a gentle, RNA-preserving lysis buffer that typically includes detergents (e.g., NP-40 or Triton X-100), protease inhibitors, and RNase inhibi...
Read more

Guideline on development and manufacture of lentiviral vectors (CHMP/BWP/2458/03)

The guideline with the reference number "CHMP/BWP/2458/03" pertains to the "Guideline on Development and Manufacture of Lentiviral Vectors." This guideline was developed by the Committee for Medicinal Products for Human Use (CHMP) and the Biotechnology Working Party (BWP) of the European Medicines Agency (EMA). It provides recommendations and regulatory guidance for the development and manufacture of lentiviral vectors, which are widely used in gene therapy and cell therapy applications. Here's an overview of the key points covered in this guideline: 1. Introduction: The guideline begins with an introduction highlighting the increasing importance of lentiviral vectors in advanced therapies and the need for guidance on their development and manufacture. 2. Scope: It defines the scope of the guideline, which covers the development and manufacture of lentiviral vectors intended for use in gene therapy and cell therapy products for human use. 3. Quality and Characte...
Read more

Stem-Loop PCR for siRNA

 Stem-loop PCR is a method often used for detecting and quantifying small RNAs, such as siRNA or miRNA, which are typically difficult to amplify directly due to their short lengths. The method involves the design of a stem-loop reverse transcription (RT) primer, which enhances specificity and stability of the short RNA during the RT-PCR process, allowing for sensitive detection and quantification of the siRNA. Here’s a detailed guide to how stem-loop PCR can be applied to siRNA detection: Key Steps in Stem-Loop PCR for siRNA Designing the Stem-Loop RT Primer : Structure : The stem-loop RT primer consists of a loop region flanked by complementary sequences on either side (the "stem"), which will fold back on itself to form a hairpin structure. Specific Binding Region : A short sequence complementary to the 3’ end of the siRNA is added at the end of the stem-loop primer to ensure specific binding to the siRNA target. Stabilization : The loop structure helps prevent primer-dimer...
Read more

FDA Guidance on Studying Multiple Versions of Cellular or Gene Therapy Products in Early-Phase Clinical Trials

 The purpose of this guidance is to offer advice to sponsors interested in conducting early-phase clinical trials for a single disease involving multiple variations of a cellular or gene therapy product. Sponsors aim to gather preliminary safety and efficacy data for these product variations within a single clinical trial. It's important to note that even though multiple product versions are studied together, each version is distinct and typically requires a separate investigational new drug application (IND) submission to the FDA. The primary goal of these early-phase clinical studies is to inform decisions about which product version(s) should be advanced for further development in later-phase trials. As such, these studies are not designed to provide the main evidence of effectiveness needed for a marketing application. They are generally not statistically powered to demonstrate a significant difference in efficacy between the different study arms. In this guidance, the FDA prov...
Read more

Stem loop RT-PCR for Detection of siRNA in Animal Tissues

Step Loop RT-PCR for Detection of Small Interfering RNA (siRNA) The recent publications described a novel used the novel method for the detection of siRNAs using a TaqMan®-based approach. This approach utilizes similar strategy that has been used for microRNA detection. The approach is illustrated in below.  In brief, the RT step occurs in the presence of a stem-loop RT primer that is complementary to the last 6–10 bases of the 3′ end of the antisense strand of the target siRNA. The stem-loop primer contains an additional universal sequence at the 5′ end that facilitates a TaqMan-based detection strategy in the subsequent qPCR step. As in the case of microRNA, the forward primer for qPCR is sequence-specific for the target siRNA. For sequence compositions that yield a low predicted melting temperature (Tm), the forward primer is designed as a tailed primer to help increase Tm. Stem Loop PCR for SiRNA Detection Step 1: Preparation of liver and plasma samples for the quanti...
Read more